Joint Corp (JYNT) valuation
Joint P/E ratio history
Joint trades at 26.0 times its earnings over the last twelve months and 17.7 times the earnings analysts expect over the next twelve. At its last 4 fiscal year ends its P/E ranged from 29.2 (year to Dec 2020) to 128.8 (year to Dec 2021), with a median of 56.9.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $8.72 | $0.20 | 43.6 | — |
| Dec 31, 2024 | $10.63 | -$0.39 | n/m | — |
| Dec 31, 2023 | $9.61 | -$0.65 | n/m | 39.1 |
| Dec 31, 2022 | $13.98 | — | n/m | — |
| Dec 31, 2021 | $65.69 | $0.51 | 128.8 | — |
| Dec 31, 2020 | $26.26 | $0.90 | 29.2 | — |
| Dec 31, 2019 | $16.14 | $0.23 | 70.2 | — |
| Dec 31, 2018 | $8.32 | $0.01 | n/m | — |
| Dec 31, 2017 | $4.96 | -$0.27 | n/m | — |
| Dec 31, 2016 | $2.65 | -$1.21 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Joint valuation against its peers
| Company | Market value | Forward P/E | Price / sales |
|---|---|---|---|
| JointJYNT | $100M | 17.7 | 1.7 |
| OrganogenesisORGO | $99.0M | — | 0.2 |
| Voyager TherapeuticsVYGR | $104M | — | 3.0 |
| Lenz TherapeuticsLENZ | $96.0M | — | 4.5 |
| CodexisCDXS | $108M | — | 1.4 |
| HumacyteHUMA | $91.0M | — | 42.9 |
| Anavex Life SciencesAVXL | $110M | — | — |
| LifemdLFMD | $111M | 21.5 | 0.5 |
| NkartaNKTX | $112M | — | — |
| Peer median | 21.5 | 2.2 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: JYNT financials · JYNT returns
No forecast, no recommendation. This page describes Joint Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.